PARKER H STEWART - 22 Apr 2021 Form 3/A - Amendment Insider Report for IMPEL NEUROPHARMA INC

Role
Director
Signature
/s/ John Leaman, M.D. as attorney-in-fact
Issuer symbol
N/A
Transactions as of
22 Apr 2021
Net transactions value
$0
Form type
3/A - Amendment
Filing time
22 Jun 2021, 17:41:45 UTC
Date Of Original Report
22 Apr 2021
Next filing
22 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMPL Series A-2 Preferred Stock 22 Apr 2021 Common Stock 7,355 Direct F1
holding IMPL Series C-1 Preferred Stock 22 Apr 2021 Common Stock 8,793 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of the issuer's Series A-2 Preferred Stock will automatically convert on a 16.37332-for-one basis into the number of shares of the issuer's Common Stock shown in column 3 immediately upon the closing of the issuer's initial public offering ("IPO"), and has no expiration date.
F2 The shares of the issuer's Series C-1 Preferred Stock will automatically convert on a 16.37332-for-one basis into the number of shares of the issuer's Common Stock shown in column 3 immediately upon the closing of the issuer's IPO, and has no expiration date.

Remarks:

This amended Form 3 is being filed to report the omission of the Series A-2 preferred stock warrant and the Series C-1 preferred stock warrant reported on Table II in the Form 3 filed on April 22, 2021 as the warrants were exercised prior to the filing of the Form 3, and to increase the number of shares underlying the derivative security to reflect the earlier exercise of each respective warrant.